/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Vaxart Inc share price today is $0.325, up -25.06%. The stock opened at $0.4297 against the previous close of $0.427, with an intraday high of $0.43 and low of $0.3.

style

pb-0

Vaxart Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.325 -0.2506(-25.06%) VXRT at 13 Mar 2026 03:51 PM Biotechnology

Lowest Today 0.3

Highest Today 0.43

Today’s Open 0.4297

Prev. Close 0.427

52 Week High 0.84

52 Week Low 0.26

Day’s Range: Low 0.3 High 0.43

52-Week Range: Low 0.26 High 0.84

Vaxart Inc Institutional Holdings

Vaxart Inc Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Vaxart Inc Fundamentals

Market Cap 184.85 M

PB Ratio 6.9086

PE Ratio 0.0

Enterprise Value 171.50 M

Total Assets 166.39 M

Volume 24017526

Vaxart Inc Company Financials

Annual Revenue FY23:776000 0.8M, FY22:107000 0.1M, FY21:892000 0.9M, FY20:4046000 4.0M, FY19:9862000 9.9M

Annual Profit FY23:null 0.0M, FY22:107000 0.1M, FY21:892000 0.9M, FY20:4046000 4.0M, FY19:9862000 9.9M

Annual Net worth FY23:-89008000 -89.0M, FY22:-107758000 -107.8M, FY21:-70470000 -70.5M, FY20:-32220000 -32.2M, FY19:-8805000 -8.8M

Quarterly Revenue Q3/2025:72413000 72.4M, Q2/2025:39730000 39.7M, Q1/2025:20876000 20.9M, Q3/2024:4933000 4.9M, Q2/2024:6401000 6.4M

Quarterly Profit Q3/2025:72413000 72.4M, Q2/2025:39730000 39.7M, Q1/2025:20876000 20.9M, Q3/2024:4933000 4.9M, Q2/2024:-11079000 -11.1M

Quarterly Net worth Q3/2025:-8141000 -8.1M, Q2/2025:-14986000 -15.0M, Q1/2025:-15591000 -15.6M, Q3/2024:-14080000 -14.1M, Q2/2024:-16466000 -16.5M

About Vaxart Inc & investment objective

Company Information Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 105

Industry Biotechnology

CEO Mr. Steven Lo

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*